Skip to main
ARVN

Arvinas Inc (ARVN) Stock Forecast & Price Target

Arvinas Inc (ARVN) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 35%
Buy 29%
Hold 29%
Sell 0%
Strong Sell 6%

Bulls say

Arvinas Inc. demonstrates a strong positive outlook due to the encouraging performance of its proprietary PROTAC technology, particularly with key product candidates like ARV-806, which has illustrated significant potency and safety advantages over existing therapies. The company's innovative approach has resulted in a competitive edge, with ARV-806 exceeding other clinical degraders in both efficacy and potential for enhanced immunotherapy effects, suggesting a promising pathway for future treatment options in KRAS G12D mutant tumors. Additionally, the anticipated approval timeline for vepdeg by the June 2025 PDUFA date reinforces confidence in the company's growth trajectory and the potential for successful market entry within the biopharmaceutical landscape.

Bears say

Arvinas Inc faces significant challenges that contribute to a negative outlook on its stock, primarily stemming from unfavorable adjustments in peak revenue projections for its lead products, which have been reduced substantially. The company's inability to defend its product portfolio raises concerns over potential market losses, particularly in the competitive landscape of oncology therapies, where efficacy metrics have not shown strong resilience. Additionally, difficulties in accessing capital may hinder critical business functions, delaying essential milestones towards achieving profitability and sustainable cash flow.

Arvinas Inc (ARVN) has been analyzed by 17 analysts, with a consensus rating of Buy. 35% of analysts recommend a Strong Buy, 29% recommend Buy, 29% suggest Holding, 0% advise Selling, and 6% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arvinas Inc (ARVN) Forecast

Analysts have given Arvinas Inc (ARVN) a Buy based on their latest research and market trends.

According to 17 analysts, Arvinas Inc (ARVN) has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.24, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.24, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arvinas Inc (ARVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.